Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Do antibody–drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study

Introduction: Antibody–drug conjugates (ADCs) produce unparalleled efficacy in refractory neoplasms but can also lead to serious toxicities. Although ADC-related sepsis has been reported, the clinical features are not well characterized in real-world studies.Objective: The aim of this study was to i...

Full description

Bibliographic Details
Main Authors: Shuang Xia, Yi-Chang Zhao, Lin Guo, Hui Gong, Yi-Kun Wang, Rui Ma, Bi-Kui Zhang, Yue Sheng, Mayur Sarangdhar, Yoshihiro Noguchi, Miao Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-11-01
Series:Frontiers in Pharmacology
Subjects:
antibody–drug conjugates
sepsis
pharmacovigilance
FAERS
data mining
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.967017/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.967017/full

Similar Items